A Study to Compare the Impact of Fulticasone Furoate/Vilanterol vs. Tiotropium on Arterial Stiffness in COPD
Status:
Completed
Trial end date:
2012-08-06
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the effect of fluticasone furoate (FF,
GW685698)/vilanterol (VI, GW642444) Inhalation Powder once daily (QD) on arterial stiffness
compared with Tiotropium QD over 12 week treatment period in subjects with COPD and aortic
pulse wave velocity (aPWV) > 12.0 m/s at Visit 1. Arterial stiffness will be measured as
aPWV. This is a comparator, randomised, double-blind, double-dummy, parallel group,
multi-centre study. Subjects who meet the eligibility criteria at Screening and meet the
randomization criteria at the end of a 2-week Run-In period will enter a 12-week treatment
period. There will be an approximate 7-day Follow-up period after the treatment period.